Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602666 | 0.93 | ADORA1 (0.63) | ADORA1SLC6A3 | |
| SCHEMBL13938165 | 0.93 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL15641582 | 0.93 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL3710188 | 0.91 | ADORA1 (0.77) | ADORA1SLC6A3 | |
| SCHEMBL3707223 | 0.91 | ADORA1 (0.74) | ADORA1SLC6A3 | |
| Hydrochloric Acid SCHEMBL3696052 | 0.91 | ADORA1 (0.76) | ADORA1SLC6A3 | |
| Potassium SCHEMBL3698784 | 0.91 | ADORA1 (0.76) | ADORA1SLC6A3 | |
| SCHEMBL3706665 | 0.91 | ADORA1 (0.76) | ADORA1SLC6A3 | |
| Potassium Ion SCHEMBL3698776 | 0.91 | ADORA1 (0.76) | ADORA1SLC6A3 | |
| SCHEMBL3706652 | 0.91 | ADORA1 (0.76) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2012-05-17 | — | — | US | disclosed |
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2012-05-17 | — | — | US | disclosed |
| WO-2009015812-A2 | PRODRUGS OF 2-AMINO-6- ( { [2- (4-CHLORPHENYL) -1, 3-THIAZ0L-4-YL] METHYL}THIO) -4- [4- ( 2 -HYDROXYETHOXY) PHENYL] PYRIDIN-3, 5-DICARBONITRILE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | TPMT, DPP4, PYGL | ADORA1 1087/4885SLC6A3 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.